EDNRA and kidney disorder: In parallel with a variety of beneficial nephroprotective effects of RAASi, selective endothelin type A receptor (ETAR) antagonists have been shown to have anti-inflammatory, antifibrotic, antiproliferative, podocyte-protective, and hemodynamic effects in models of kidney diseases.14